# EDGAR Filing Document

**Accession Number:** 0001533998
**File Stem:** 0001104659-23-024920
**Filing Date:** 2023-2
**Character Count:** 12269
**Document Hash:** 5a264facc847fcbc249b638a67599204
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-024920.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001104659-23-024920

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230222

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DarioHealth Corp.
- **CENTRAL INDEX KEY:** 0001533998
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 452973162
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37704
- **FILM NUMBER:** 23662223

**BUSINESS ADDRESS:**
- **STREET 1:** 18 W 18TH ST., 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011
- **BUSINESS PHONE:** 646.665.4667

**MAIL ADDRESS:**
- **STREET 1:** 18 W 18TH ST., 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LabStyle Innovations Corp.
- **DATE OF NAME CHANGE:** 20111101

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): February 22, 2023

**DARIOHEALTH CORP.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37704** | **45-2973162** |
| (State or other jurisdiction <br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**18 W. 18th St, 5th Floor**

**New York** **, New York 10019**

(Address of Principal Executive Offices)

**972- 4-770-4055** 

(Issuer's telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br> Symbol(s)** | **Name of exchange on which <br> registered** |
| Common Stock, par value $0.0001 per share | DRIO | The Nasdaq Capital Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On February 22, 2023, on the recommendation of the Nominating Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, expanded the Board by one seat and appointed Jon Kaplan as a member of the Board, effective immediately.

Mr. Kaplan, 55, has extensive business experience consulting and advising healthcare companies. From September 2018 until July 2020, Mr. Kaplan served on the Board of Directors, and the audit committee, of Quorum Health Corporation. Since 2007, he has served as a Senior Partner and Managing Director of the Boston Consulting Group, Inc., or BCG, a privately-held company focused on providing management consulting services, where he recently served on BCG's global leadership council and as the practice leader of BCG's healthcare services. Mr. Kaplan, previously served in advisory board roles at digital health leaders Livongo, Transcarent, Circulation, and Picwell. Prior to BCG, Mr. Kaplan held senior roles at Accenture, Pricewaterhousecooper and Ernst & Young. Mr. Kaplan received a M.B.A. from the Kellogg Graduate School of Management at Northwestern University, a Masters of Public Health from the University of Pittsburgh and a B.A. in Economics from Cornell University. Mr. Kaplan brings to the Board valuable experience from his roles consulting and advising healthcare companies.

As remuneration for his service as a director, Mr. Kaplan will receive the same fees as the Company's other non-executive directors. There is no arrangement or understanding between Mr. Kaplan and any other person pursuant to which he was elected as a director, and except as otherwise described herein, there are no transactions in which Mr. Kaplan has an interest requiring disclosure under Item 404(a) of Regulation S-K.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On February 23, 2023, the Company issued a press release announcing the appointment of Mr. Kaplan to its Board. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

<u>Exhibit Number</u>   <u>Description</u> <br> [99.1](tm237767d1_ex99-1.htm) [Press release dated February 23, 2023.](tm237767d1_ex99-1.htm) <br> 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: February 24, 2023 | **DARIOHEALTH CORP.** | **DARIOHEALTH CORP.** |
|  | By: | /s/ Zvi Ben David |
|  | Name: | Zvi Ben-David |
|  | Title: | Chief Financial Officer, Treasurer and Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

**Dario Appoints Industry Veteran Jon Kaplan to Board**

*Mr. Kaplan brings a wealth of experience in business strategy specifically in healthcare and digital health*

New York, N.Y. – February 23, 2023 -- DarioHealth Corp. (Nasdaq: DRIO)(the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the appointment of Jon Kaplan to serve as a board member effective immediately.

Mr. Kaplan is a Managing Director and Senior Partner at Boston Consulting Group (BCG), serving as a core member of the strategy and health care practices and leading BCG's transformation initiative for the future evolution of healthcare in the United States and its impact globally. He has previously served in advisory board roles at digital health leaders Livongo, Transcarent, Circulation, and Picwell and brings deep knowledge and connections across the health care industry.

Prior to BCG, Mr. Kaplan held senior roles at Accenture, Pricewaterhousecooper and Ernst & Young. He is a graduate of the Kellogg School of Management, Northwestern University; has an MPH from University of Pittsburgh; and a B.A. from Cornell University.

"We are pleased to welcome Jon to our board as he brings broad and deep knowledge of the entire health care industry and sees the potential for Dario to have a transformative impact for our clients and partners. Jon's arrival comes at a critical time for Dario as we focus on building the right strategic relationships to position Dario for long-term success," said Erez Raphael, CEO at Dario.

"It's an exciting time to join the Dario board as the company navigates the opportunities that come with rapid growth. I believe the company's successful shift to become a leader in multi-chronic digital health care was extremely well-timed as the demand for more scalable solutions continues to grow, and I look forward to helping Dario capitalize on these opportunities," said Jon Kaplan.

**About DarioHealth Corp.**

DarioHealth Corp. (Nasdaq: DRIO) is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Making the right thing to do the easy thing to do.

Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. To learn more about DarioHealth and its digital health solutions, or for more information, visit <u>http://dariohealth.com</u>.

**Cautionary Note Regarding Forward-Looking Statements**

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when the Company discusses its belief that the company has potential to have a transformative impact for its clients and partners and that its successful shift to become a leader in multi-chronic digital health care was extremely well-timed as the demand for more scalable solutions continues to grow. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

**DarioHealth Corporate Contact**

Mary Mooney

VP Marketing

mary@dariohealth.com

+1-312-593-4280

**Media Contact:**

Scott Stachowiak

<u>Scott.Stachowiak@russopartnersllc.com</u>

+1-646-942-5630